LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven newly hired employees as a means to attract ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will ...

As of December 31, 2024, the company had cash, cash equivalents and short-term investments of $196.3M. “Completing submission of the BLA is an ...

LANGHORNE, Pa., March 26, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9 ...